Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Cytokinetics (CYTK) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's President and CEO, Robert I. Blum, will deliver a presentation on Monday, January 13, 2025, at 9:00 AM Pacific Time in the Borgia Room of the Westin St. Francis Hotel in San Francisco.
Interested investors and stakeholders can access the presentation through a live webcast available on the Investors & Media section of the Cytokinetics website. The recording will remain accessible on the company's website for 90 days following the event's conclusion.
Cytokinetics (CYTK) ha annunciato la sua partecipazione alla 43ª Conferenza annuale J.P. Morgan Healthcare. Il Presidente e CEO dell'azienda, Robert I. Blum, terrà una presentazione lunedì 13 gennaio 2025, alle 9:00 AM ora del Pacifico nella Sala Borgia del Westin St. Francis Hotel a San Francisco.
Gli investitori e le parti interessate possono accedere alla presentazione tramite un webcast dal vivo disponibile nella sezione Investitori e Media del sito web di Cytokinetics. La registrazione rimarrà accessibile sul sito dell'azienda per 90 giorni dopo la conclusione dell'evento.
Cytokinetics (CYTK) ha anunciado su participación en la 43ª Conferencia Anual de J.P. Morgan Healthcare. El Presidente y CEO de la compañía, Robert I. Blum, ofrecerá una presentación el lunes 13 de enero de 2025, a las 9:00 AM hora del Pacífico en la Sala Borgia del Hotel Westin St. Francis en San Francisco.
Los inversores y partes interesadas pueden acceder a la presentación a través de un webcast en vivo disponible en la sección de Inversores y Medios del sitio web de Cytokinetics. La grabación permanecerá accesible en el sitio web de la compañía durante 90 días después de la conclusión del evento.
사이토키네틱스 (CYTK)는 제43회 JP 모건 헬스케어 컨퍼런스에 참여할 것이라고 발표했습니다. 회사의 사장 겸 CEO인 로버트 I. 블룸(Robert I. Blum)은 2025년 1월 13일 월요일 오전 9시 태평양 표준시에 샌프란시스코의 웨스틴 세인트 프랜시스 호텔 보르지아 룸에서 발표할 예정입니다.
관심 있는 투자자와 이해관계자는 사이토키네틱스 웹사이트의 투자자 및 미디어 섹션에서 실시간 웹캐스트를 통해 발표에 접근할 수 있습니다. 녹화된 내용은 행사 종료 이후 90일 동안 회사 웹사이트에서 확인할 수 있습니다.
Cytokinetics (CYTK) a annoncé sa participation à la 43e Conférence annuelle de J.P. Morgan Healthcare. Le Président et Directeur Général de la société, Robert I. Blum, présentera une communication lundi 13 janvier 2025, à 9h00 heure du Pacifique dans la salle Borgia de l'hôtel Westin St. Francis à San Francisco.
Les investisseurs et parties prenantes intéressés peuvent accéder à la présentation via un webinaire en direct, disponible dans la section Investisseurs et Médias du site web de Cytokinetics. L'enregistrement restera accessible sur le site de la société pendant 90 jours après la conclusion de l'événement.
Cytokinetics (CYTK) hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare-Konferenz bekannt gegeben. Der Präsident und CEO des Unternehmens, Robert I. Blum, wird am Montag, den 13. Januar 2025, um 9:00 Uhr Pazifischer Zeit im Borgia-Raum des Westin St. Francis Hotel in San Francisco eine Präsentation halten.
Interessierte Investoren und Stakeholder können die Präsentation über einen Live-Webcast in der Rubrik Investoren & Medien der Cytokinetics-Website abrufen. Die Aufzeichnung wird für 90 Tage nach Abschluss der Veranstaltung auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 9:00 AM Pacific Time in the Borgia Room of the Westin St. Francis Hotel in San Francisco, CA.
Interested parties may access the live webcast of the presentation by visiting the Investors & Media section of the Cytokinetics website at http://www.cytokinetics.com. The webcast replay will be archived on the Cytokinetics website for 90 days following the conclusion of the event.
About Cytokinetics
Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Cytokinetics is readying for the potential commercialization of aficamten, a next-in-class cardiac myosin inhibitor following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.
For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics’ product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlined in Cytokinetics' filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.
Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757
FAQ
When is Cytokinetics (CYTK) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch CYTK's J.P. Morgan Healthcare Conference presentation?
How long will CYTK's J.P. Morgan Conference presentation replay be available?
Where is CYTK's 2025 J.P. Morgan Healthcare Conference presentation taking place?
